Liberate Bio develops non-viral delivery technologies for nucleic acid cargoes, aiming to address genetic disorders.
Liberate Bio has raised $31.0M in total funding. The most recent round was Seed. The last funding was announced in October 2025.
Liberate Bio's investors include Khosla Ventures.
Liberate Bio is headquartered in Boston, United States.
Liberate Bio develops non-viral delivery technologies for nucleic acid cargoes, aiming to address genetic disorders.
Liberate Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Liberate Bio — Funding & Investors." VCBacked, October 15, 2025, https://www.vcbacked.co/company/liberate-bio. Accessed October 31, 2026.
VCBacked. (2025). Liberate Bio — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/liberate-bio
{{cite web |title=Liberate Bio — Funding & Investors |url=https://www.vcbacked.co/company/liberate-bio |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated